Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.
Bernard A. Fox, PhD
Advertisement
Articles by Bernard A. Fox, PhD
Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5